排名前五的靶点	数量

FLT3(酪氨酸蛋白激酶受体FLT3)	1
PORCN(PorcupineO-酰基转移酶)	1
SMN2(运动神经元存活蛋白)	1
TNF-α(肿瘤坏死因子α)	1
HIF-2α(内皮PAS结构域包含蛋白-1)	1

关联

项与 Thermo Fisher Scientific, Inc. 相关的药物

Lenacapavir Sodium

来那帕韦钠

靶点

HIV-1 capsid

作用机制

HIV-1 capsid抑制剂

在研机构

Gilead Sciences Ireland UC [+7]

原研机构

Gilead Sciences, Inc.

在研适应症

HIV感染

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2022-08-17

Quizartinib Hydrochloride

奎扎替尼

靶点

FLT3

作用机制

FLT3抑制剂

在研机构

Daiichi Sankyo Europe GmbH [+5]

原研机构

Ambit Biosciences Corp.

在研适应症

急性髓性白血病 [+2]

非在研适应症

急性淋巴细胞白血病 [+7]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2019-06-18

Nusinersen sodium

诺西那生钠

靶点

SMN2

作用机制

SMN2刺激剂 [+1]

在研机构

Biogen, Inc. [+6]

原研机构

Ionis Pharmaceuticals, Inc.

在研适应症

神经肌肉疾病 [+1]

非在研适应症

I型脊髓性肌萎缩症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2016-12-23

468

项与 Thermo Fisher Scientific, Inc. 相关的临床试验

NCT06247241

/ Not yet recruiting临床2期

A Phase 2a, Open-Label, First-In-Human, Two-Part, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Efficacy Of VMB-100 In Female Subjects With Moderate Stress Urinary Incontinence

The study drug VMB-100 is an mRNA encoding for IGF-1. It is administered by injection into the urethra sphincter, and taken up by the muscle cells. The IGF-1 acts to promote muscle regeneration in the sphincter, which is expected to improve the function of the sphincter and thereby alleviate incontinence (urinary leakage).

开始日期2025-09-01

申办/合作机构

Versameb AG

[+1]

NCT05948579

/ Not yet recruiting临床2期IIT

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention B - Vilazodone will assess the safety and efficacy of vilzodone in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.

开始日期2025-06-01

申办/合作机构

Cambridge Cognition Ltd.

[+5]

NCT06816433

/ Not yet recruiting临床2期IIT

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design.
Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.

开始日期2025-06-01

申办/合作机构

Cambridge Cognition Ltd.

[+5]

100 项与 Thermo Fisher Scientific, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Thermo Fisher Scientific, Inc. 相关的专利（医药）

登录后查看更多信息

11,571

项与 Thermo Fisher Scientific, Inc. 相关的文献（医药）

2025-12-31·Channels

Biophysical and structural mechanisms of epilepsy-associated mutations in the S4-S5 Linker of KCNQ2 channels

Article

作者: Yang, Yen-Yu ; Chang, Hsueh-Kai ; Yang, Shi-Bing ; Wong, Swee-Hee ; Lee, Inn-Chi

Mutations in KCNQ2 are linked to various neurological disorders, including neonatal-onset epilepsy. The severity of these conditions often correlates with the mutation's location and the biochemical properties of the altered amino acid side chains. Two mutations affecting aspartate at position 212 (D212) in the S4-S5 linker of KCNQ2 have been identified. Interestingly, while the charge-conserved D212E mutation leads to severe neonatal-onset developmental and epileptic encephalopathy (DEE), the more dramatic substitution to glycine (D212G) results in self-limited familial neonatal epilepsy (SLFNE), a much milder pathology. To elucidate the underlying mechanisms, we performed electrophysiological studies and in silico simulations to investigate these mutations' biophysical and structural effects. Our findings reveal that the D212E mutation stabilizes the channel in the voltage sensor down-state and destabilizes the up-state, leading to a rightward shift in the voltage-dependent activation curve, slower activation kinetics, and accelerated deactivation kinetics. This disruption in KCNQ2 voltage sensitivity persists even in the more physiologically relevant KCNQ2/3 heterotetrameric channels. In contrast, the D212G mutation primarily destabilizes the up-state, but its impact on voltage sensitivity is significantly reduced in KCNQ2/3 heterotetrameric channels. These findings provide key insights into the biophysical and structural basis of KCNQ2 D212 mutations and their contribution to epilepsy-related symptoms, offering a clearer understanding of how these mutations drive the varied clinical outcomes observed in patients.

2025-04-21·Cancer Research

Abstract 2061: Monitoring PD-L1 expression in cancer associated macrophage-like cells in blood predicts clinical outcomes in metastatic cancer patients treated with PD-L1 immunotherapies

作者: Lin, Steven H. ; Tang, Cha-Mei ; Ho, H. ; Kasabwala, Dimpal M. ; Cristofanilli, Massimo ; Ho, Thai H. ; Adams, Daniel L. ; Reduzzi, Carolina

AbstractStudies have described the efficacy of immunotherapies (IMT) utilizing programmed death 1 receptor and its ligand (PD-L1) for treating solid tumors. However, many patients (pts) fail to respond to IMT, underscoring the need for better predictive biomarkers for improved pt identification and stratification. Poor IMT responses are often attributed to the dynamic nature of PD-L1 which may change after chemotherapy or radiation and is quantified by static immunostaining. Recently, studies have described PD-L1 upregulation in giant phagocytic stromal cells, i.e. Cancer associated macrophage-like cells (CAML), circulating macrophages that have engulfed tumors before entering circulation and may predict IMT responses. We conducted a pilot study to monitor the peripheral blood of n=46 metastatic cancer pts undergoing systemic treatment with IMT in combination with other therapies, to evaluate CAML PD-L1 prior to and post IMT induction with clinical correlation at 2 years. In a prospective pilot study of n=46 metastatic cancer pts, breast (n=14), non-small cell lung (n=24), and renal cell (n=8), all starting new lines of systemic chemotherapy in combination with IMT (pembrolizumab [n=30], nivolumab [n=13], Durva [n=1], or atezolizumab [n=3]) for newly diagnosed recurrent metastasis (n=24) or with previously treated progressive metastatic disease (n=22). We isolated CAMLs from 7.5 ml baseline (T0) blood using the LifeTracDx® PD-L1 test and scored PD-L1 as high or low. If possible, a follow-up sample (T1) was taken (∼48 days) after IMT induction. Pts’ progressive free survival (PFS) and overall survival (OS) hazard ratios (HRs) were analyzed by censored univariate analysis based on RECIST v1.1 over 2 years. T0 PD-L1 CAML data was available for 89% (n=41/46) of pts, with 39% (n=16/41) having high CAML PD-L1 which was not correlated with improved PFS (HR=0.9, p=0.985, CI=0.5-1.9) or OS (HR=1.0, p=0.899, CI=0.4-2.2). T1 PD-L1 CAML data was available for 74% (n=34/46) of pts, with 53% (n=18/34) having high CAML PD-L1, which significantly correlated with improved PFS (HR=2.9, p=0.012, CI=1.3-6.4) and OS (HR=5.5, p=0.0005, CI=2.2-13.6). In comparing CAML PD-L1 change post IMT, it was found that consistently low PD-L1 at T0 & T1 had the poorest responses, median PFS (mPFS)=2.3 months and median OS (mOS)=5.5 months. In contrast, consistently high PD-L1 at T0 & T1 had better responses, mPFS=6.1 months and mOS=16.7 months. Further, pts who increased in CAML PD-L1 after IMT had the best response rates, mPFS=10.3 months and mOS=14.8 months. Here, we describe a cancer agnostic blood-based biopsy to monitor dynamic PD-L1 changes in circulating tumor immune cells and predict clinical benefit to PD-L1 IMTs in several cancer types. While this initial pilot study appears to stratify pts with better IMT responses, larger validation studies are needed.Citation Format:Dimpal M. Kasabwala, Steven H. Lin, Massimo Cristofanilli, Carolina Reduzzi, Cha-Mei Tang, Thai H. Ho H. Ho, Daniel L. Adams. Monitoring PD-L1 expression in cancer associated macrophage-like cells in blood predicts clinical outcomes in metastatic cancer patients treated with PD-L1 immunotherapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2061.

2025-04-21·Cancer Research

Abstract 1989: Heterogeneity of epithelial, mesenchymal, progenitor, and stem cell phenotypes on CTCs correlates to clinical outcomes in metastatic cancer patients

作者: Cristofanilli, Massimo ; Reduzzi, Carolina ; Adams, Daniel L. ; Tsai, Susan ; Duffy, Alexis B. ; Aldakkak, Mohammed ; Tang, Cha-Mei ; Chumsri, Saranya

AbstractCirculating tumor cells (CTCs) are cancer cells that detach from tumors, enter the blood and seed distant sites. CTCs spread as single cells, or cluster aggregates, and can be heterogenous with differing biological phenotypes, i.e. epithelial, mesenchymal, progenitor, & stem cell. Three clinically relevant CTC subtypes are often described in patients (pts) 1) CTCs with normal epithelial traits (strong filamentous cytokeratin (CK+ & CD45-/CD14-), 2) Epithelial-mesenchymal CTCs (EMTs), cancer cells with downregulated epithelial & upregulated mesenchymal traits (low diffused CK+, CD45-/CD14-) and 3) tumor-macrophage fusion cells (TMFCs), cancer cells that fuse with macrophages (polynucleated DAPI+, diffuse CK+ and CD14+/CD45+). To better elucidate the biological and clinical importance of the 3 CTC subtypes, we isolated CTCs by a marker agnostic method from the blood of n=49 metastatic cancer pts. We then enumerated and phenotypically subtyped CTCs comparing clinical utility of clustering and CTC heterogeneity over 2 years. Peripheral blood samples were collected from 49 metastatic cancer pts, breast (n=38), pancreatic (n=9), colon (n=3), lung (n=1), and prostate (n=1). Whole blood (7.5mL) was filtered by size exclusion using CellSieve microfilters and fluorescently stained for CD45, CD14, CK, and DAPI to identify CTCs, EMTs and TMFCs. Cells were imaged, enumerated and fluors quenched by the QUAS-R technique; followed by re-stained for CD44, CD24, CD133, CD144, N-Cadherin, EpCAM, and Vimentin. Markers were categorized as negative, low, medium, or high. A heterogeneity biomarker score was developed as high, 2-3 log deviations between marker expression, or low 0-1. Pt progressive free survival (PFS) and overall survival (OS) were analyzed over 2 years. CTCs were found in 40% of pts, EMTs in 51%, & TMFCs in ∼93%. For subtyping, CD44 was in CTCs 88%, EMTs 59%, & TMFCs 91%; CD24 in CTCs 40%, EMTs 41%, & TMFCs 6%; CD133 in CTCs 100%, EMTs 8%, & TMFCs 100%; CD144 in CTCs 100%, EMTs 77%, & TMFCs 82%; N-cadherin in CTCs 100%, EMTs 0%, & TMFCs 45%; Vimentin in CTCs 51%, EMTs 100%, & TMFCs 83%; EpCAM in CTCs 74%, EMTs 12%, & TMFCs 20%. CTCs and EMTs were found to have high heterogeneity in 30% of samples in both individual cells and clusters, with a high biomarker heterogeneity significantly correlated with poorer outcomes (PFS: HR=15.4, p=0.0014, CI=3.4-68.9; OS: HR=12.4, p=0.0056, CI=2.6-59.1). TMFCs were found to have high heterogeneity, 40% of samples, but this was not correlated with outcomes. In this pilot study, it appeared that isolated CTC, EMTs and TMFCs subtypes have differing heterogenous expressions of epithelial, mesenchymal, progenitor, and stem cell markers. Further, high rates biomarker heterogeneity in CTCs and EMTs, but not TMFCs, correlated with faster rates of progression & death. Larger validation experiments with biomarker stratification is ongoing.Citation Format:Alexis B. Duffy, Massimo Cristofanilli, Carolina Reduzzi, Cha-Mei Tang, Saranya Chumsri, Susan Tsai, Mohammed Aldakkak, Daniel L. Adams. Heterogeneity of epithelial, mesenchymal, progenitor, and stem cell phenotypes on CTCs correlates to clinical outcomes in metastatic cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1989.

2,341

项与 Thermo Fisher Scientific, Inc. 相关的新闻（医药）

2025-05-01

·PRNewswire

In Vitro Diagnostics: Technologies Transforming Global Healthcare Markets

" In vitro diagnostics (IVD) refers to tests performed outside the body to detect diseases, monitor health, or guide treatments. These technologies are revolutionizing global healthcare by enabling early diagnosis, personalized medicine, and improved patient outcomes. " BOSTON, May 1, 2025 /PRNewswire/ -- According to the latest study from BCC Research, In Vitro Diagnostics: Technologies and Global Markets is projected to grow from $94.7 billion in 2024 to $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.Boston: According to the latest study from BCC Research, In Vitro Diagnostics: Technologies and Global Markets is projected to grow from $94.7 billion in 2024 to $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029. This report analyzes in vitro diagnostic (IVD) technologies and devices used in hospitals and point-of-care (POC) settings, focusing on market trends, drivers, opportunities, and competitive intelligence. It segments the market by technology, application, end user, and region, with forecasts through 2029. Interesting facts: Artificial Intelligence (AI) has revolutionized the healthcare industry. The report explores how companies are integrating AI into IVD devices. POC testing is increasingly used over traditional hospital and clinic-based diagnostics, with demand surging post-pandemic. Haematology remains a widely practiced test type compared to diagnostic microbiology, driven by a global rise in blood-related disorders. Factors contributing to the market's growth include: Rise in the population of older adults and dependency on frequent diagnosis procedures : The growing number of older adults is increasing the need for frequent diagnostic procedures to manage age-related health conditions. This trend is driving demand for advanced and accessible diagnostic solutions. Integration of artificial intelligence in IVD : AI is being integrated into in vitro diagnostics to improve the accuracy and speed of disease detection. This technology helps provide more personalized and efficient healthcare solutions. Rising incidence of chronic diseases: The rising incidence of chronic diseases, such as diabetes and heart conditions, is increasing the need for ongoing monitoring and diagnostic tests. This trend is fueling the demand for advanced diagnostic technologies. Improving the quality of POC testing: This is making health diagnostics faster, more accurate, and easily accessible, especially in remote or urgent care settings. Request a Sample Copy of the In Vitro Diagnostics: Technologies and Global Markets Report Synopsis Questions A ddressed: What is the projected market size and growth rate? The market is projected to grow from $87.8 billion in 2023 to $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period. What are the factors driving the growth of the market? Rise in the aging population and dependency on frequent diagnosis procedures, Integration of AI in IVD, rising incidence of chronic diseases and improving the quality of POC testing. What market segments are covered in the report? The market is segmented by technology, application and end user. Which technology segment will be dominant over the forecast period? The haematology segment is anticipated to dominate the market through the end of 2029. Which region has the largest market share? North America holds the largest market share. Market leaders include : Abbott Becton, Dickinson and Co. Biomerieux Bio-Rad Laboratories Inc. Bio-Techne Bruker Danaher Corp. EKF Diagnostics Holdings Plc F. Hoffmann-La Roche Ltd. Hologic Inc. JSR Corp. Quidelortho Corp. Siemens Healthineers AG Sysmex Corp. Thermo Fisher Scientific Inc. Related reports include: In Vitro Diagnostics (IVD) Quality Controls: Global Market: The global market for in vitro diagnostics (IVD) quality controls focuses on ensuring the accuracy and reliability of diagnostic tests. As demand for precise diagnostics grows, the need for high-quality control systems in IVD devices is growing worldwide. In Vitro Diagnostics (IVD) Analyzers: Global Market : The global market for IVD analyzers is driven by the rising demand for efficient and accurate diagnostic testing. These analyzers play a crucial role in disease detection and monitoring. Purchase a copy of the report direct from BCC Research. For further information on these reports or to purchase one, please contact [email protected]. About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help readers make informed business decisions, free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: [email protected] Phone: +1 781-489-7301 For media inquiries, email [email protected] or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: SOURCE BCC Research LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

诊断试剂

2025-04-30

·PRNewswire

RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing

FREDERICK, Md., April 30, 2025 /PRNewswire/ -- RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science. This collaboration aims to accelerate the availability of new, potentially life-saving cell and exosome therapies that have the potential to revolutionize the treatment of degenerative disease. Uniting RoosterBio's extensive portfolio of hMSC-based products and processes with Thermo Fisher's advanced therapy GMP contract manufacturing capabilities, customers can access a new comprehensive solution for the development and manufacturing of hMSC and exosome therapeutics. Specifically, biopharmaceutical companies will utilize RoosterBio's expertise in hMSC and exosome products, processes, and analytics along with Thermo Fisher's leading GMP manufacturing capabilities to accelerate their timelines for production of clinical trial materials. Manufacturing services provided by Thermo Fisher will include upstream expansion of hMSCs, downstream purification of MSCs and MSCderived exosomes, and drug product manufacturing. "Thermo Fisher has an exceptional track record of success in the manufacture of clinical and commercial cell and gene therapies and a well-established global network to meet the needs of our customers," said Tim Kelly, Chief Executive Officer of RoosterBio. "Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities. Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to work with Thermo Fisher to translate our MSC and exosome technologies into advanced therapy products for patients around the world." "Our collaboration with RoosterBio reflects our shared commitment to helping lifechanging therapies reach patients in need, in the safest, fastest and most effective way possible," said Ben Castro, Vice President and General Manager, Large Molecule, pharma services, Thermo Fisher. "We're excited to work with the team to expand our Contract Development Manufacturing Organization (CDMO) services and support our biotechnology partners through the research and optimization, process development and manufacturing of critical treatments." Consistent with global best practices, RoosterBio prioritizes the safety and efficacy of its products through robust bioethical standards, including hMSCs being sourced under stringent guidelines, manufactured using highly standardized processes, and supported by first-in-class characterization. About RoosterBio RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by clients' success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale. For more information, please visit SOURCE RoosterBio, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

细胞疗法

2025-04-29

·医药健闻

美敦力前高管担任奥林巴斯新CEO；默克宣布39亿美元收购SpringWorks；诺和诺德赢得重大法律胜利 | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态奥林巴斯公司（Olympus）董事会一致决定任命美敦力前执行副总裁兼内外科产品组合总裁Bob White接替奥林巴斯董事、代表执行官、总裁兼首席执行官Yasuo Takeuchi，自2025年6月1日起生效。Bob还将在定于2025年6月举行的奥林巴斯股东大会上被提名为董事会候选人。在加入美敦力之前，Bob曾在GE医疗、Merge Healthcare和IBM医疗保健部门担任领导职务。德国医疗保健和材料集团默克(Merck KGaA)周一表示，已达成协议，将以39亿美元的股权价值收购美国生物技术公司SpringWorks Therapeutics，以加强其抗癌药物业务。SpringWorks总部位于美国康涅狄格州的斯坦福德，于2019年在纽约上市。该公司开发治疗癌症和罕见肿瘤的药物，目前在市场上有两种产品。诺和诺德(Novo Nordisk)取得了一场重大的法律胜利，这在很大程度上限制了配制药店营销或销售该制药商的畅销减肥药维格威(Wegovy)和糖尿病治疗药物奥泽美匹克(Ozempic)的更便宜且未经批准的仿制版本。得州联邦法官周四晚间作出关键裁决，驳回了复合药房行业协会的初步禁令申请，维持美国食品药品监督管理局(FDA)关于糖尿病药物Ozempic和减肥药Wegovy活性成分司美格鲁肽(semaglutide)“供应短缺状态已结束”的认定。安进（Amgen）正在加倍扩大其在美国的生产业务，并计划对其位于俄亥俄州中部的工厂进行重大升级。安进表示，该公司将投资9亿美元扩建其位于俄亥俄州新奥尔巴尼的生物制造工厂。该项目预计将使该州的安进的工作岗位总数达到750个，并将公司在俄亥俄州的总投资增加到14亿美元以上。艾伯维计划未来十年内在美国投资数十亿美元，目标是到2035年在美国投资100亿美元，以支持其当前的增长计划，并扩展到肥胖等新领域。这笔款项的一部分将专门用于建造四个新的美国生产设施，专门用于活性药物成分（API）、药品、肽和设备。赛默飞世尔科技（Thermo Fisher Scientific）表示，未来四年将在美国额外投资20亿美元。承诺的四分之三资金将支持赛默飞世尔的制造业务，而剩余的5亿美元将扩大其研发工作。赛默飞世尔已经拥有由64个美国工厂组成的广泛网络，覆盖37个州。该公司在其他43个国家也有业务。截至去年年底，该公司的全球员工人数约为125,000人，其中超过50,000人在美国工作。4月28日，恒瑞医药宣布，其发行H股计划正式获得中国证监会备案，拟发行不超过8.15亿股普通股赴港上市。这是继2000年A股上市后，恒瑞首次通过股权融资“补血”，也是其国际化战略的关键一步。依据此前披露的IPO计划，若成功登陆港股，恒瑞拟将募资20亿美元（约145亿元人民币）主要用于海外研发中心建设、全球多中心临床试验及国际化销售网络扩张。首药控股拟以自有及自筹资金不超过7.87亿元，在亦庄新城国际医药创新公园（BioPark）自主建设新的“首药控股新药研发与产业化基地”项目，并与北京经济技术开发区管委会签署《经济发展合作协议》。该合作协议生效后，公司将按照招拍挂供应程序取得项目宗地，建设包括研发中心、质控中心、临床试验中心、销售中心及生产基地在内的公司新总部，建设期3年。科源制药公告，拟收购山东宏济堂制药集团股份有限公司99.42%股权，交易作价约35.81亿元。同时拟定增募资不超7亿元。宏济堂是国内知名的阿胶产品生产企业。宏济堂与科源制药均为“力诺系”旗下公司，二者实控人均为高元坤。科源制药2023年4月登陆创业板上市，主要从事化学原料药及其制剂产品的研发、生产和销售。康弘药业公告，公司全资子公司北京康弘生物医药有限公司拟吸收合并北京弘健医疗器械有限公司、四川康弘中药材种植有限公司拟吸收合并成都康弘医药贸易有限公司、四川济生堂药业有限公司拟吸收合并四川济生堂兴尚生物科技有限责任公司。吸收合并后，北京康弘生物、康弘种植、济生堂存续经营，公司名称、股权结构保持不变。产业动态美敦力（Medtronic）宣布与Dragonfly Endoscopy达成战略合作，正式将后者研发的Dragonfly胰胆内窥镜系统引入美国市场。这一协议标志着胰胆疾病诊疗领域数十年来首次迎来重大技术升级。根据协议，美敦力将于2024年内率先在美国20家顶尖学术医疗中心及综合性医院启动Dragonfly系统的临床应用，未来三年逐步覆盖全美。美敦力宣布，其自主研发的全球最小直径无腔除颤导线OmniaSecure正式获得美国食品药品监督管理局（FDA）批准，用于右心室植入治疗危及生命的心律失常疾病。波士顿科学宣布，针对FARAPULSE脉冲电场消融（PFA）系统和辅助使用FARAPOINT PFA导管治疗持续性心房颤动（AF）患者的ADVANTAGE AF临床试验第二阶段达成12个月的主要安全性和有效性终点。该研究的主要结果已在圣地亚哥举行的第二届PFA现场手术峰会上公布，并同时在《Circulation》杂志上发表。益普生与上药控股有限公司达成战略合作协议。双方将围绕达菲林展开合作，通过加强资源整合和渠道覆盖，进一步推动达菲林产品在中国市场的深度覆盖。达菲林作为常用的促性腺激素释放激素类药物（GnRHa），在前列腺癌、中枢性性早熟、子宫内膜异位症、女性不孕症、子宫肌瘤的术前治疗等多种疾病中被广泛应用。复星医药控股子公司复宏汉霖与Alvogen Korea签订《许可协议》，复宏汉霖授予Alvogen Korea于许可区域（即韩国）及领域（即广泛期小细胞肺癌（ES-SCLC）、非鳞状非小细胞肺癌（nsNSCLC）、转移性结直肠癌（mCRC）、胃癌（GC）和食管鳞状细胞癌（ESCC）适应症）独家商业化斯鲁利单抗注射液的权利。Alvogen Korea应就许可产品向复宏汉霖支付至多1450万美元。基于许可产品于许可区域的年度净销售额达成情况，Alvogen Korea应依约向复宏汉霖支付至多9750万美元的商业销售里程碑款项。易瑞生物公告，公司与Chr. Hansen A/S（科汉森）签署合同，约定的2025-2029年度销售目标合计为7305.77万欧元，折合约6.01亿元人民币。合作内容包括公司在指定区域内授权科汉森独家销售、分销及推广公司产品，主要产品为乳中抗生素残留筛查测试、黄曲霉毒素M1筛查及定量测试、三聚氰胺及乳清掺假测试等。合同自2025年6月16日起生效，持续有效期为5年。以岭药业公告，公司全资孙公司万洋衡水制药有限公司提交的“来曲唑”化学原料药上市申请已获国家药品监督管理局批准。来曲唑是一种高效、选择性非甾体类芳香化酶抑制剂，用于乳腺癌治疗。君实生物宣布，由公司自主研发的抗PD-1单抗药物特瑞普利单抗注射液（拓益®）用于不可切除或转移性黑色素瘤的一线治疗的新适应症上市申请于近日获得国家药品监督管理局（NMPA）批准。这是特瑞普利单抗在中国内地获批的第12项适应症。信达生物宣布，第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）靶向药物奥壹新（利厄替尼片）的新药上市申请获得国家药品监督管理局批准，用于具有表皮生长因子受体（EGFR）外显子19缺失（19DEL）或外显子21置换突变（L858R）的局部晚期或复发转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。奥壹新（利厄替尼片）是目前唯一获批上市的，以萘胺结构为基础的第三代EGFR-TKI药物。清华人工智能医院正式揭牌成立，建设将分阶段进行，初期将在清华AI全面布局和多学科医工交叉的基础上，建设AI医院系统，依托北京清华长庚医院及北京清华长庚互联网医院试运行，以全科医学科和眼科、放射诊断科、呼吸科等专科为试点。未来，将构建“AI+医疗+教育+科研”生态闭环，促进优质医疗资源的高效扩容与均衡布局。联系美通社+86-10-5953 9500info@prnasia.com

高管变更IPO并购

100 项与 Thermo Fisher Scientific, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Thermo Fisher Scientific, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年05月26日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床申请

临床1期

临床2期

临床3期

申请上市

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

门冬酰胺酶 ( ASN )	急性淋巴细胞白血病更多	批准上市
阿达木单抗生物类似药 (Alvotech) ( TNF-α )	类风湿关节炎更多	批准上市
双氯芬酸钠 ( COXs )	-	申请上市
来那帕韦钠 ( HIV-1 capsid )	-	申请上市
奎扎替尼 ( FLT3 )	伴有 FLT3/ITD 突变的急性髓系白血病更多	申请上市